Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AAVAnc80-hOTOF Gene Therapy in OTOF-Mediated Hearing Loss
2023-505128-76-00Phase 2Authorised
- Sponsor
- Akouos
- Start
- Oct 2023
- Modality
- Gene Therapies
- Countries
- 5
01
Overview
Phase 2, open-label trial of AK-OTOF in autosomal recessive nonsyndromic deafness 9 (DFNB9) and sensorineural hearing loss (SNHL) (3 cohorts), sponsored by Akouos. Primary endpoint: Safety: frequency of adverse events related to AAVAnc80-hOTOF or administration procedure. Planned start Oct 2023; status: authorised.
02
Drugs
AK-OTOF
03
Conditions
autosomal recessive nonsyndromic deafness 9 (DFNB9)sensorineural hearing loss (SNHL)
Beyond the preview
Go deeper on 2023-505128-76-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505128-76-00.